Toxina botulínica tipo A: propriedades farmacológicas e uso clínico
DOI:
https://doi.org/10.11606/issn.2317-0190.v11iSupl.1a102495Palavras-chave:
Toxina Botulínica Tipo AResumo
Todas as informações contidas neste trabalho de revisão são referentes a toxina botulínica do tipo A (TBA) produzida por Allergan Inc, representada no Brasil por Allergan Produtos Farmacêuticos, cujo nome comercial é BOTOX®. A toxina botulínica do tipo-A é um agente biológico obtido laboratorialmente, sendo uma substância cristalina estável, liofilizada em albumina humana e apresentada em frasco a vácuo estéril, para ser diluída em solução salina. A TBA é produzida naturalmente pelo Clostridium botulinum, uma bactéria anaeróbia, que produz oito tipos sorológicos de toxina, sendo a do tipo-A a mais potente e por isto utilizada clinicamente.
Downloads
Referências
Bernard C. An introduction to the study of experimental medicine. New York: Mac Millan; 1927.
Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 1997; 40(3):317-27.
Boni R, Kreyden OP, Burg G. Revival of the use of botulinum toxin: application in dermatology. Dermatology. 2000; 200(4):287-91.
Benedetto AV. The cosmetic uses of botulinum toxin type A. Int J Dermatol. 1999;38(9):641-55.
Huag W, Rogachefsky AS, Foster JA. Browlift with botulinum toxin. Dermatol Surg. 2000;26(1): 55-60.
Binder WJ, Blitzer A, Brin MF. Treatment of hyperfunctional lines of the face with botulinum toxin A. Dermatol Surg. 1998; 24(11):1198-205.
Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;52:80-99.
Schantz EJ, Johnson EA. Quality of Botulinum toxin for human treatment. In: Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press; 1993. p. 657-59.
Hatheway CL, Dang C. Immunogenicity of neutoxins of clostridium botulinum. In: Therapy with botulinum toxin. New York: Marcel Decker, 1994. p. 93-107.
Schantz EJ, Johnson EA. Quality of botulinum toxin for humam treatment. In: Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press; 1993. p. 657-59.
Rossetto O, Seveso M, Caccin P, Schiavo G, Montecocco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon 2001;39(1):27-41.
Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248(Suppl 1):3-10.
Johnson EA. Biomedical aspects of botulinum toxin. J. Toxicol-Toxin Reviews. 1999;18(1):1-15.
Poulain B, Fréderic D, Colasante C, Molgo J. Cellular and molecular mode of action of botulinum and tetanus neurotoxins. In: Advances in organ biology. Jai Press Inc; 1997. p. 285-313.
Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, et al. Botulinum neutoxin A selectivity cleaves the synaptic protein SNAP-25. Nature. 1993;365:160-3.
Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon. 2001;39(12):1815-20.
Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996; 46(1):26-9.
Montecucco C, Tonello F. Bontoxilysin. In: Handbook of proteolytic enzymes. New York: Academy Press; 1998. p. 1-5.
Rossetto O, Deloye F, Poulain B, Pellizzari R, Schiavo G, Montecucco C. The metallic-proteinase activity of tetanus and Botulinum neurotoxins. J Physiol 1995;89:43-40.
Rossetto O, Deloye F, Poulain B, Pellizzari R, Schiavo G, Montecucco C. The metallo-proteinase activity of tetanus and botulism neurotoxins. J Physiol Paris. 1995;89(1):43-50.
Panicker JN, Muthane UB. Botulinum toxins: pharmacology and its current therapeutic evidence for use. Neurol India. 2003; 51(4):455-60.
Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies - therapeutic consequences. Exp Neurol. 1997;147(1):96-102.
Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol. 1992;239:16-20.
Johnson EA. Biomedical aspects of botulinum toxin. J Toxicol-Toxin Reviews. 1999;18(1):1-15.
Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al. Botulinum toxin type B: a double-blind placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49(3):701-7.
Johnson EA. Biomedical aspects of botulinum toxin. J Toxicol Toxin Rev. 1999;18:1-15.
Bandyopadhyay S, Clark AW, DasGupta BR, Sathyamoorthy V. Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. J Biol Chem. 1987;262:2660-3.
Malizio CJ, Goodnough MC, Johnson EA. Purification of clostridium botulinum type A neurotoxin. In: Methods in molecular biology - bacterial toxins - methods and protocols. Totowa: Human Press; 2000. p. 27-39.
Ohishi I. Oral toxicities of clostridium botulinum type A and B toxins from different strain. Infect Immum. 1984;43:487-90.
Bandyopadhyay S, Clark AW, DasGupta BR, Sathyamoorthy V. Role of heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. J Biol Chem. 1997;262(6):2660-2663.
Coflield JA, Considiner RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallett M: Neurologycal disease and therapy. Therapy with botulinum toxin. 1994;25:3-13.
Lebeda F J, Hack DC, Gentry MK. Theorical analyses of the functional regions of the heavy chain of botulinum neurotoxin. In: Jankovic J, Hallett M. Neurologycal disease and therapy. Therapy with botulinum toxin. 1994;25:51-61.
Coflield JA, Considiner RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallett M. Neurological disease and therapy. Therapy with botulinum toxin. 1994;25:3-13.
Lebeda FJ, Hack DC, Gentry MK. Theorical analyses of the functional regions of the heavy chain of botulinum neurotoxin. In: Jankovic J, Hallett M. Neurological disease and therapy. Therapy with botulinum toxin. 1994;25:153-1178.
Gracies JM, Simpson DM. Botulinum toxin therapy. The neurologist. 2000;6(2):98-110.
Alderson K, Holds JB, Anderson RL. Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology. 1991;41(11):1800-5.
Gracies JM, Simpson DM. Botulinum toxin therapy. Neurologist. 2000;6:98-110.
Hexsel D, Almeida AT. Cosmetic use of botulinum toxin. Porto Alegre: Age Editora; 2000.
Hirokawa N, Kitamura M. Binding of clostridium botulinum neurotoxin to the presynaptic membrane in the central nervous system. J Cell Biol. 1979;81:43-9.
Wiegand H, Erdmann G, Wellhöner HH. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Arch Pharmacol. 1994;292:161-165.
Wiegand H, Erdmann G, Wellhoner HH. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol. 1976;292(2):161-5.
Hatheway CL, Ferreira J. Detection and identification of clostridium botulinum neurotoxins. In: Natural toxins II. Plenum Press; 1996. p. 481-98.
Aoki KR. Pharmacology of BOTOX (botulinum toxin type A) purified neurotoxin complex: Local versus systemic muscle activity measurements in mice. Eur J Neurol. 1995;2:3-9.
Gracies JM. Effects of botulinum toxin type A dilution and endplate targeting technique in upper limb spasticity. Ann Neurol;52 (1 Supply):S89-271.
Wienkers K, Helveston EM, Ellis FD, Cadera W. Botulinum toxin injection into rabbit vitreous. Opht Surg. 1984;15(4):310-4.
Rockville MD. Botulinum toxin type A - BOTOX - purified neurotoxin complex TBX-A, Oculinum. In: Biopharma: Biopharmaceutical products in the US market. Biotechnology Information Institute. 2001;(332):271-274.
Matarasso SL. The role of clostridium botulinum: a neurotoxin in clinical dermatology. West J Med. 1998;169(4):226.
Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg. 1999;103(2):645-62.
Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg. 1998;24(11):1179-80.
Moore P, Naumann M. Handebook of botulinum toxin Treatment. 2nd ed. Maldem: Blackwell Sciences; 2003.
Oliveira MV, Oliveira AP. Toxina botulínica no tratamento de rugas faciais. Disponível em: http:www.cosmedical.com.br/botox.htm
Garcia A, Fulton JE. Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose response study. Dermatol Surg. 1996;22:39-43.
Zechmeister M, Dal’Forno TO. Conservação, diluição e estocagem após a diluição. In: Hexsel D, Almeida AT. Cosmetic use of botulinum toxin. Porto Alegre: Age Editora; 2000. p. 43- 45.
O’Brien C, Yablon S. Management of spasticity with botulinum toxin. Colorado: Postgraduate Institute for Medicine; 1995. p. 1-33.
Zechmeister M, Dall'Fomo TO. Conservação, diluição e estocagem após a diluição. In: Hexsel D, Almeida AT. Cosmetic use of botulinum toxin. Porto Alegre: Age; 2000. p. 43-45.
Yablon SA. Botulinum neurotoxin intramuscular chemodenervation- role in management of spastic hipertonia and related motor disorders. Phys Med Rehabil Clin North Am. 2001;12(4):833-874.
Fulton JE. Botulinum toxin. The Newport Beach experience. Dermatol Surg. 1998;24(11):1219-24.
Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcomes in primates. Plast Reconstr Surg. 2000;105(6):1948-53.
Guerrissi J. Intraoperative injection of botulinum toxin A into orbicularis oculi muscle for the treatment of crow’s feet. Plast Reconstr Surg. 2000;105(6):2219-25.
Ahn HY, Park MY, Park DH, Han GG. Botulinum toxin A for the treatment of facial hyperkinetic wrinkles lines in Koreans. Plast Reconstr Surg. 2000;105(2):778-84.
Carruthers J, Carruthers A. Treatment of glabelar frown lines with C. botulinum – an exotoxin. J Dermatol Surg Oncol. 1992;18(1):17-21.
Stratigos AJ, Arndt HA, Dover JS. Advances in coetaneous aesthetic surgery. JAMA. 1998;280(16):1397-8.
Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg. 1999;103(2):645-62.
Hamjian JA, Walter FO. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve. 1994;17:1385.
Hankins CL, Strimling R, Rogers GS. Botulinum toxin for glabelar wrinkles. Dose and response. Dermatol Surg. 1998;24(11):1181-3.
Brenner R, Madhusoodanan S, Korn Z, Spitzer M. Acute anxiety and depression induced by loss of sensation and muscle control after botulinum toxin A injection [letter]. South Med J. 1999;92(7):738.
Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg. 1998;24(4):1249-54.
Childers MK. Use of Botulinum toxin type A in pain management. Columbia: BookMaster; 1999. p. 1-127.
Fields KA. Skin breakthroughs in the year 2000. Int J Fertil Women’s Med. 2000;45(2):175-81.
Keen M, Blitzer A, Aviv J, Binder W, Prystowsky J, Smith H, et al. Botulinum toxin A for hyperkinetic facial lines: results of double-blind, placebo controlled study. Plast Reconstr Surg. 1994;94(1):94-9.
Song KH. Botulinum toxin type A injections for the treatment of frown lines. Ann Pharmacother. 1998;32(12):1365-7.
Klein AW, Wexler P, Carruthers A, Carruthers J. Treatment of facial furrows and rhytids. Dermatol Clin. 1997;15:595.
Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg. 1999;103(2):701-13.
Dressler D. Botulinum toxin therapy. Stuttgard: Georg Thieme Verlag; 2000. p. 1-192.
Paul T, Horn E, Shepherd R, Dahms G. Comparison of chemodenervation to standard strabismus surgery. Invest Ophthalmol Vis Sci. 2001;42(4):S168.
Dressler D. Botulinum toxin therapy. New York: Georg Thieme Verlag; 2000.
Moguel-Anchieta S, Dixon-Olivera S, Martinez-Oropeza S, Orozco-Gomez LP. Botulinum toxin as a treatment for strabismus in systemic diseases. Arch Soc Esp Oftalmol. 2003;78(1):9-14.
Broniarczyk-Loba A, Nowakowska O, Laudanska-Olszewska I, Omulecki W. Advancements in diagnosis and surgical treatment of strabismus in adolescents and adults. Klin Oczna. 2003;105(6):410-413.
Moguel S, Martinez-Oropeza S, Orozco L. Treatment of strabismus associated with brain damage using botulinum toxin. Tratamiento con toxina botulinica para estrabismo en retraso psicomotor (SPA). Arch Soc Esp Oftalmol. 2004;79(9):443-8.
Broniarczyk-Loba A, Nowakowska O, Laudanska-Olszewska I, Omulecki W. Advancements in diagnosis and surgical treatment of strabismus in adolescent and adults. Klin Oczna. 2003;105(6):410-3.
Forget R, Tozlovanu V, Iancu A, Boghen D. Botulinum toxin improves lid opening delays in blefarospasm associated apraxia od lit opening. Neurology. 2002;58(12):1843-6.
Ahmed F, Magar R, Marchetti A, Findley L, Larson JP, Pirtosek Z, et al. Retrospective evaluation of the dose od Dysport and Botox in the clinical management od cervical distonia or blepharospam (the real dose study) - expansion of the real dose study. Paris: 8th Congress of the European Federation of Neurological Societies; 2004.
Ziak P. Results of long term therapy of essential blepharospam and facial hemispasm with botulotoxin A. Ceska Slov Oftalmol. 2004;60(1):37-44.
Dodel RC, Kirchner A, Koehne-Volland R, Künig G, Ceballos-Baumann A, Naumann M, et al. Cost of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmaco Economics. 1997;12(6):695-706.
Ziak P. Results of long term treatment of essential blepharospasm and facial hemispasm with botulinum toxin A. Cesk Slov Oftalmol. 2004;60(1):37-44.
Drummond GT, Hinz BJ. Botulinum toxin for blefarospasm and hemifacial spasm: stability of duration of effect and dosage over time. Can J Ophthalmol. 2001;36(7):398-403.
Oyama H, Ikeda A, Inoue S, Nakashima Y, Shibuya M. Local injection of botulinum toxin type A for hemifacial spasm. Neurol Ned-Chir. 2002;42(6):245-9.
Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical distonia. Neurology. 2000;55(12): S15-21.
Brashear A. The botulinum toxins in the treatment of cervical dystonia. Semin Neurol. 2000;21(1):85-90.
Hsiung G-YR, Das SK, Ranawaya R, Lafontaine A-L, Suchowersky O. Long-term efficacy of botulinum toxin A in the treatment of various movement disorders over a 10 year period. Mov Dis. 2002;17(6):1288-1293.
Gupta M, Singh G, Khwaja G. Botulinum toxin in the treatment of dystonias - a hospital based study. J Assoc Physicians India. 2003;51:447-453.
Pascual J. Influencia del tratamento com toxina botulínica tipo A sobre las cefaleas primarias em pacientes con distonia craneocervical. Neurologia. 2004;19(5):260-263.
Scott BL. Evaluation and treatment of dystonia. South Med J. 2000;93(8):746-751.
Muller J, Wenning GK, Wissel J, Seppi K, Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol. 2002;249(3):300-304.
Kumar R. Subthalamic nucleus deep brain stimulation (stn dbs)-induced dystonia and management with botulinum toxin (Botox) injections. Mov Disord. 2002;17(Suppl 5):S211.
Szliwowski HB, Van Bogaert P, Goldman S, Petillon J-P, Abou Azar N, Zegers de Beyl D. Multidisciplinary treatment approach and botulinum toxin in a selected case of dystonic hemisyndrome. Dev Med Child Neurol. 2002;44(Suppl 92):51-52.
Kumar R. Subthalamic nucleus deep brain stimulation (stn dbs)-induced dystonia and management with botulinum toxin (Botox) injections. Mov Disord. 2002;17(Suppl 5):S211.
Ragothaman M, Sarangmath N, Jayaram S, Swaminath PV, Muthane U. Task-specific dystonia in tabla players. Mov Disord. 2004;19(10):1254-1256.
Hannan S, Nguyen T. Treatment of severe progressive hereditary chorea with acquired dystonia. J Neurol. 2004;251 (Suppl 3):III/126-7.
Lianza S. Espasticidade – conceitos atuais baseados em evidências científicas. Associação Médica Brasileira. Consenso 2002-2004.
Gaebler-Spira D, Revivo G. The use of botulinum toxin in pediatric disorders. Phys Med Rehabil Clin North Am. 2003;14(4):703-725.
Mayer NH, Simpson DM. Spasticity – a we move self-study CME activity-etiology, evaluation, management, and role of botulinum toxin. WEMOVE/CME; 2002. p.1-173.
Boyd RN, Morris ME, Graham HK. Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol. 2001;8(supp 5):150-166.
Balkrishnan R, Camacho F, Smith BP, Koman AL. Longitudinal examination of outcomes associated with botulinum toxin use in children with cerebral palsy. Value in Health. 2003;6:183S.
Boyd RN, Morris ME, Graham HK. Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol. 2001;8 (Suppl 5):150-66.
Houltram J, Noble I, Boyd RN, Corry I, Flett P, Grahan HK. Botulinum toxin type A in the management of equines in children with cerebral palsy: an evidence-based economic evaluation. Eur J Neurol. 2001;8(suppl 5):194-202.
Hesse S, Brandl-Hesse B, Bardeleben A, Werner C, Funk M. Botulinum toxin A treatment of adult upper and lower limb spasticity. Drugs Aging. 2001;18(4):255-262.
Esquinaze A, Mayer N. Botulinum toxin for the management of muscle overactivity and spasticity after stroke. Curr Atheroscler Rep. 2001;3(4):295-8.
Almeida ART, Hesxel DM. Hiperidrose e toxina botulínica. São Paulo: Know-how Editorial; 2003.
Naumann M, Hojman U, Bergmann I, Hamm H, Tojka KV, Reiners F. Focal hyperhidroses. Effective treatment with intracutaneous botulinum toxin. Arch.Dermatol. 1998;134:301-304.
Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323:596–9.
Naumann M, Lowe NJ, Kumar CR, Hamm H. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol. 2003;139:731–6.
Lowe PL, Cerdan-Sanz S, Lowe NJ. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Dermatol Surg. 2003;29:545–8.
Naumann MK, Hamm H, Lowe NJ. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol. 2002;147:1218–26.
Swartling C, Naver H, Lindberg M. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol. 2001;8:247–52.
Campanati A, Penna L, Guzzo T, Menotta L, Silvestri B, Lagalla G, et al. Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther. 2003;25(1):298-308.
Bodokh I. Hyperhidrose palmaire. Ann Dermatol Venereol. 2003;130:561–4.
Bodokh I, Branger E. Traitement de l’hyperhidrosis palmaire per toxine botulique: etude comparative. Ann Dermatol Venereol. 2001;128:833–4.
Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2002;28(9):822-7.
Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg. 1999;103(2):701-13.
Guerrissi J. Intraoperative injection of botulinum toxin A into orbicularis oculi muscle for the treatment of crow’s feet. Plast Reconstr Surg. 2000;105(6):2219-25.
Borodic GE. Botulinum A toxin for (expressionistic) ptosis overcorrection after frontalis sling. Ophthal Plast Reconstr Surg. 1992;8(2):137-42.
Wieder JM, Moy RL. Understanding botulinum toxin. Surgical anatomy of the frown, forehead, and periocular region. Dermatol Surg. 1998;24(11):1172-4.
Sposito MMM. Anatomia topográfica e funcional da face e sua importância na aplicação de toxina botulínica. In: Hexsel D, Almeida AT. Uso cosmético da toxina botulínica. Porto Alegre: Age Editora; 2000. p. 88-98.
Brandt FS, Bellman B. Cosmetic use of botulinum A exotoxin for the aging neck. Dermatol Surg. 1998;24:1232-4.
Sposito MMM. Anatomia topográfica e funcional da face e sua importância na aplicação de toxina botulinica. In: Hexsel D, Almeida AT. Uso cosmético da toxina botulinica. Porto Alegre: Age; 2000. p. 137-42.
Huang W, Rogachefsky AS, Fostr JA. Browlift with botulinum toxin. Dermatol Surg 2000;26(1):56-60.
Sposito MMM. Toxina botulinica, relaxamento muscular e qualidade de vida. In: Hexsel D, Almeida AT. Uso cosmético da toxina botulinica. Porto Alegre: Age; 2000. p. 28-31.
Zachery CB. Botulinum toxin type A: special characteristics and injection techniques for men. Cosmet Dermatol. 2004;17(11): 699-702.
Lowe NJ. Cosmetc therapy: glabelar and forehead area. Opr Tech Otorri-head and neack surg. 2004;15(2):128-133.
Carruthers A, Carruthers J, Lowe NJ, Menter A, Gibson J, Nordquist M, et al. One-year, randomized, multicenter, two-period study of the safety and efficacy od repeated treatments with botulinum toxin type A in patients with glabelar lines. J Clin Res. 2004;7:1-20.
Brin MF, Jankovic J. Other uses of botulinum toxin type A. In: Brin MF, Comella CL, Jankovis J. Distonia: Etiology, clinical features and treatment. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 213-228.
Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope. 2001;11(2):218-226.
Brin MF, Jankovic J. Other uses of botulinum toxin type A. In: Brin MF, Comella CL, Jankovis J. Distonia: Etiology clinical features and treatment. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 213-228.
Presthus J. Botulinum toxin typeA for the treatment of vulvodynia. Cui Naunyn Schmiedebergs Arch Pharmacol. 2002;365:R17.
Issac C, Gimenez R, Ruiz RO. Rugas de colo. In: Hexsel D, Almeida, AT. Cosmetic use of botulinum toxin. Porto Alegre: Age Editora; 2000. p. 178-181.
Brian MF. Botulinum toxin therapy: basic science and therapeutic overview of other applications. In: Blitzer A, Binder WJ, Boyd JB, Carruthers A. Management of facial lines and wrinkles. New York: Lippincott Williams & Wilkins; 2000. p. 270-303.
Issac C, Gimenez R, Ruiz RO. Rugas de colo. In: Hexsel D, Almeida AT. Uso cosmético da toxina botulinica. Porto Alegre: Age; 2000. p. 178-181.
Brian MF. Botulinum toxin therapy: basic science and therapeutic overview of other applications. In: Blitzer A, Binder WJ, Boyd JB, Carruthers A. Managent of facial lines and wrinkles. New York: Lippincott Willians & Wilkins; 2000. p. 270-303.
Cardoso Jr A, Savassi-Rocha PR, Coelho LGV, Sposito MMM. Esvaziamento gástrico e curva ponderal em obesos classe III submetidos à injeção de toxina botulínica na região antropilórica [dissertação]. Belo Horizonte: Universidade Federal de Minas Gerais; 2004.
Bushara KO. Sialorrhea in amyotrophic lateral scleroses: a hypothesis of a new treatment- botulinum toxin A injections of the parotid glands. Med Hypotheses. 1997;48:337-339.
Porta M, Gamba M, Bertacchi G, Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry. 2001;70(4):538-40.
Schulte-Baukloh H, Michael TH, Stürzebecher B, Knispel HH. Botulinum – A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol. 2004;44(1):139-43.
Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003;62(2):259-64.
Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, Johnson E, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2003;278(2):1363-71.
Benecke R. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in treatment of cervical distonia. Mov Disor. 2004;19(suppl9):S10-11.
Roggenkämper P. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in treatment of cervical blepharospasm. Mov Disor. 2004;19 (suppl 9):S84-5.
Benecke R. Efficacy and safety of a new botukinum toxin type A free of complexing proteins in treatment of cervical distonia. Mov Disor. 2004;19 (Suppl 9):S10-11.
Roggenkamper P. Efficacy and safety of a new botukinum toxin type A free of complexing proteins in treatment of cervical blepharrospasm. Mov Disor. 2004;19 (Suppl 9):S84-5.
Aoki KR, Wheeler LA. A preclinical comparison of the local muscle weakening efficacy, saftey and antigenic potencial of botulinum neurotoxin sertotypes A, B and F. Neurology. 2000;54(11) Suppl 3:A199.
Eleopra R, Botulinum neurotoxin sertypes C and E: clinical trials. In: Brian MF, Hallett M, Jankovic J. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002.
Foster KA. Novel toxin developments: delivery of endopeptidase activity of botulinum neurotoxin to new targets cells. In: Brian MF, Hallet M, Jankovic J. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002.
Greene PE. Long term use of botulinum toxin type F to treat patients resistant to botulinum toxin type A. In: Brian MF, Hallet M, Jankovic J. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002.
Li Y, Foran P, Lawrence G, Mohammed N, Chan-Kwo-Chion CK, Lisk G, et al. Recombinant forms of tetanus toxin engineered for examining and exploiting neuronal trafficking pathways. J Biol Chem. 2001;276(33):31394-401.
Hallet M. Immunotoxin. In: Brian MF, Hallet M, Jankovic J. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002.
Johnson EA. Hybrid and chimeric botulinum toxin molecules. In: Brian MF, Hallet M, Jankovic J. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002.
Jankovic J, Esquinazi A, Fehlings D, Freitag F, Lang A, Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol 2004; 27(5): 234-44.
Fishman PS. Neuronal delivery vestors derived from tetanus toxin. In: Brian MF, Hallet M, Jankovic J. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2004 Acta Fisiátrica
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
